The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EVAX | +4.22% | N/A | N/A | -99% |
| S&P | +15.98% | +86.41% | +13.26% | +77% |
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
No news articles found for Evaxion A/s.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $37.47K | -75.7% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $3.44M | -77.3% |
| Market Cap / Employee | $74.70K | 0.0% |
| Employees | 46 | -6.1% |
| Net Income | -$4,892.26K | 21.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.75M | 84.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.74M | 7.3% |
| Short Term Debt | $540.01K | 13.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.79% | 31.3% |
| Return On Invested Capital | -187.10% | -2.5% |
No data available for this period.
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 234.36 | -3.59 | 1.60 | -2.08 | -135.82% |
| Price to Sales | 5.20 | 1.45 | 3.10 | 4.86 | -91.38% |
| Price to Tangible Book Value | 67.15 | 18.25 | 1.60 | -2.08 | -107.16% |
| Return on Equity | -320.1% | -803.1% | -205.7% | -321.4% | -74.07% |
| Total Debt | $10.87M | $10.49M | $0.00K | $11.28M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
